LYTIR

Company · RGNX

REGENXBIO Inc.

Nasdaq's symbol directory lists RGNX on Nasdaq as “REGENXBIO Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 2 occasions ($949K); insiders sold on 3 occasions ($718K); 1 filing by holders of 5% or more; 3 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $949K in total; Insider sales: $718K in total.Jun: Insider sales $216KJul: Insider sales $502KAug: Insider purchases $949KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $949KInsider sales below: $718K
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Ciongoli Gregory Austin bought on 2 days latest Aug 27, 2026 bought $949K
  2. PAKOLA STEVE, Chief Medical Officer sold on 3 days all under a 10b5-1 plan latest Jul 2, 2026 sold $718K
Every trade (5)
  1. BUYCiongoli Gregory Austin bought Aug 27, 2026 53,407 shares filing $500K
  2. BUYCiongoli Gregory Austin bought Aug 26, 2026 49,196 shares filing $450K
  3. SELLPAKOLA STEVE, Chief Medical Officer sold Jul 2, 2026 2,161 shares 10b5-1 plan (scheduled) filing $29K
  4. SELLPAKOLA STEVE, Chief Medical Officer sold Jul 1, 2026 36,725 shares 10b5-1 plan (scheduled) filing $472K
  5. SELLPAKOLA STEVE, Chief Medical Officer sold Jun 29, 2026 19,608 shares 10b5-1 plan (scheduled) filing $216K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. JPMORGAN CHASE & CO. filed Oct 13, 2026 Schedule 13G passive 3,560,915 shares filing 5.3%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Nov 5, 2026
  2. Departure or appointment of directors or officers filing Oct 16, 2026
  3. Entry into a material definitive agreement filing Sep 23, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.